Conditions: Healthy
Keywords: Bioequivalence Healthy Subjects
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: yes

Brief summary:
This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under non-fasting conditions.

Detailed description:

Arms:
arm 1: Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg arm 2: Aricept® Orally Disintegrating Tablets, 10 mg

Interventions: intervention 1: Donepezil Hydrochloride intervention 2: Aricept®
Intervention descriptions: intervention 1: 10 mg Orally Disintegrating Tablet intervention 2: 10 mg Orally Disintegrating Tablet

Protocol document: